Cyclerion Therapeutics (CYCN) Capital Expenditures (2018 - 2020)

Cyclerion Therapeutics' Capital Expenditures history runs 3 years deep, the most recent figure standing at $35000.0 for Q4 2020.

• In Q4 2020, Capital Expenditures fell 79.89% year-over-year to $35000.0; the TTM figure through Mar 2025 stood at $35000.0 (changed N/A YoY), while the FY2021 annual figure was $7000.0, down 99.54% from the prior year.
• Capital Expenditures was $35000.0 for Q4 2020 at Cyclerion Therapeutics, down from $1.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.2 million in Q2 2019 to a low of -$1.2 million in Q4 2018.
• Historically, Capital Expenditures has averaged $738916.7 across 3 years, with a median of $237000.0 in 2018.
• The sharpest annual moves came in 2019 and 2020: Capital Expenditures jumped 1315.67% in 2019, then slumped 100.71% in 2020.
• A 3-year view of Capital Expenditures shows it stood at -$1.2 million in 2018, then jumped by 114.91% to $174000.0 in 2019, then plunged by 79.89% to $35000.0 in 2020.
• The last three Capital Expenditures figures came in at $35000.0 (Q4 2020), $1.5 million (Q3 2020), and -$30000.0 (Q2 2020), per Business Quant data.